FluroTech Ltd. (TEST.V)
| Previous Close | 0.1100 |
| Open | 0.1100 |
| Bid | 0.1500 x 0 |
| Ask | 0.1600 x 0 |
| Day's Range | 0.1100 - 0.1750 |
| 52 Week Range | 0.0600 - 0.8500 |
| Volume | 948,075 |
| Avg. Volume | 197,950 |
| Market Cap | 18.103M |
| Beta (5Y Monthly) | -1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0490 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
FluroTest Provides System Development Update; Reports Point of Access Test System and Immunoassay for SARS-CoV-2 Detection is Fully Functional
CALGARY, Alberta, Nov. 19, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a developer of diagnostics technology in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today provided a progress update on its efforts to bring its Pandemic Response Platform to market. FluroTest has been developing its “Pandemic and Emerging Disease Defense Platform” since la
- GlobeNewswire
FluroTest Provides System Development Update; Reports Saliva-based Point of Access Test System and Immunoassay for SARS-CoV-2 Detection is Fully Functional
CALGARY, Alberta, Sept. 16, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today provided a progress update on efforts to bring its Pandemic Response Platform to market. Notable product developments include: Platform Development: FluroTest’s entire “end-to-end” Pandemic
- GlobeNewswire
FluroTest Announces Pre-Emergency Use Authorization Filing with FDA; Provides Executive Update on Program Progress
CALGARY, Alberta, July 12, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced it has filed its Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA). The Pre-EUA submission is the Company’s latest step taken as it
